The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...
Regulators have approved the drug as a treatment for weight loss, Type 2 diabetes and lowering the risk of heart attacks and ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...
The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.
The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive risks of opioids.
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...
The drug offered more relief than a placebo in clinical trials, though it does not appear more effective than other pain ...
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...